Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion official investor newsroom · 行业原文收录 · 来源发布：Wed Aug 05 2026 10:30:38 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:50 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program August 5, 2026 at 6:30 AM EDT PDF Version Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug discovery REC-4881
以上为带出处的原文节选，完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。